How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States

Journal of Clinical Oncology

Volumn 25, Issue 2, 2007, Pages 175-179

  Ramsey, Scott D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BEVACIZUMAB; CETUXIMAB; LENALIDOMIDE; SUNITINIB;

CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; KIDNEY CARCINOMA; LONG TERM CARE; MEDICAL TECHNOLOGY; MYELODYSPLASTIC SYNDROME; NON PROFIT ORGANIZATION; PRIORITY JOURNAL; REVIEW; UNITED STATES; ECONOMICS; NEOPLASM; NOTE; ONCOLOGY;

COST CONTROL; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; UNITED STATES;

EID: 33846973643     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.9805     Document Type: Review

References (29)

1. National Center for Charitable Statistics: A program of the Center of Nonprofits and Philanthropy at the Urban Institute. Washington, DC, National Center for Charitable Statistics, 2006
2. Nadler E, Eckert B, Neumann PJ: Do oncologists believe new cancer drugs offer good value? Oncologist 11:90-95, 2006
3. Ringel J, Hosek S, Vollaard B, et al: The Elasticity of Demand for Health Care: A Review of the Literature and its Application to the Military Health System. Santa Monica, CA, National Defense Research Institute and RAND Health, 2005
4. Gladwell M: The moral hazard myth: The bad idea behind our failed health care system. The New Yorker, August 29, 2005: 44-49
5. Jacobson M, O'Malley AJ, Earle CC, et al: Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) 25:437-443, 2006
6. National Cancer Institute, Bethesda, MD: Treatment choices for men with early-stage prostate cancer. http://www.cancer.gov/cancertopics/pdq/treatment
7. The Medical Letter. www.medicalletter.org
8. Drugstore.com. www.drugstore.com
9. Calfee JE, Villarreal M, DuPré E: An exploratory analysis of pharmaceutical price disparities and their implications among six developed nations. Aei-Brookings Joint Center for Regulatory Studies, April 2006
10. US Preventive Services Task Force: Screening for Colorectal Cancer: Recommendations and Rationale. Rockville, MD, Agency for Healthcare Research and Quality, 2002
11. Sonnenberg A, Delco F, Inadomi JM: Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 133:573-584, 2000
12. Bondi MA, Harris JR, Atkins D, et al: Employer coverage of clinical preventive services in the United States. Am J Health Promot 20:214-222, 2006
13. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
14. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
15. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
16. Chernew M, Cutler DM, Keenan PS: Increasing health insurance costs and the decline in insurance coverage. Health Serv Res 40:1021-1039, 2005
17. Newhouse JP: How much should Medicare pay for drugs? Health Aff (Millwood) 23:89-102, 2004
18. Institute of Medicine: Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC, National Academies Press, 2003
19. Neumann PJ: Why don't Americans use cost-effectiveness analysis? Am J Manag Care 10:308-312, 2004
20. Prosser LA, Koplan JP, Neumann PJ, et al: Barriers to using cost-effectiveness analysis in managed care decision making. Am J Manag Care 6:173-179, 2000
21. Fendrick AM, Smith DG, Chernew ME, et al: A benefit-based copay for prescription drugs: Patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 7:861-867, 2001
22. Reinhardt UE: An information infrastructure for the pharmaceutical market. Health Aff (Millwood) 23:107-112, 2004
23. Fox J: Medicare should, but cannot, consider cost: Legal impediments to a sound policy. Buffalo L Review 53:577-633, 2005
24. Pharmaceutical Research and Manufacturers of America: Pharmaceutical Industry Profile 2006. Washington, DC, PhRMA, 2006
25. Ubel PA, DeKay ML, Baron J, et al: Cost-effectiveness analysis in a setting of budget constraints: Is it equitable? N Engl J Med 334:1174-1177, 1996
26. Stiggelbout AM, Elstein AS, Molewijk B, et al: Clinical ethical dilemmas: Convergent and divergent views of two scholarly communities. J Med Ethics 32:381-388, 2006
27. Holloway RG, Ringel SP, Bernat JL, et al: US neurologists: Attitudes on rationing. Neurology 55:1492-1497, 2000
28. Holmberg L, Bill-Axelson A, Helgesen F, et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781-789, 2002
29. Bill-Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984, 2005